aXichem AB Class A (DE:A6X)
FRANKFURT:A6X
A6X Stock Chart & Stats
€0.21
<€0.01(1.32%)
At close: 4:00 PM EST
€0.21
<€0.01(1.32%)
Day’s Range― - ―
52-Week Range€0.07 - €0.32
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.80M
Enterprise Value€92.85M
Total Cash (Recent Filing)€6.78M
Total Debt (Recent Filing)€3.09M
Price to Earnings (P/E)―
Beta-0.50
Next Earnings
Aug 27, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding67,729,120
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)2.33
Price to Sales (P/S)6.68
P/FCF Ratio-7.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€3.53M
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthA ~55% YoY revenue acceleration in 2025 shows the business is gaining commercial traction and expanding end-market adoption. Sustained top-line growth over multiple quarters can support scale-related margin improvement, greater bargaining power with customers, and a clearer path to eventual profitability.
Low Financial LeverageVery low debt-to-equity (~0.09) reduces bankruptcy risk and preserves financial flexibility. This allows management to fund R&D, commercial roll-out or absorb short-term operating losses without immediate debt-servicing strain, lengthening runway for execution on commercial initiatives.
Proprietary Active Ingredient/IPA focused technology platform built around proprietary phenylcapsaicin provides an intellectual-property foundation and potential product differentiation. Durable IP and a single active ingredient can enable multiple market applications, licensing opportunities, and higher barriers to entry versus commodity chemistries.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow indicate the business is not self-funding and relies on external capital. Over months this raises dilution and refinancing risk, limits reinvestment capacity, and creates execution risk if capital markets become less accessible or financing terms worsen.
Deeply Negative ProfitabilityDeeply negative gross and operating margins signal unfavorable unit economics or high fixed costs versus current volumes. Without durable margin improvement from pricing, cost reductions, or scale, sustained losses will impede free cash flow generation and the company’s ability to reinvest for growth.
Eroding Equity / Negative ROEDeclining equity and persistently negative ROE reflect cumulative losses that erode the capital base. Over the medium term this reduces financial resilience, may constrain strategic options, and increases the likelihood of future equity raises that dilute existing holders if profitability is not restored.
aXichem AB Class A News
A6X FAQ
What was aXichem AB Class A’s price range in the past 12 months?
aXichem AB Class A lowest stock price was €0.07 and its highest was €0.32 in the past 12 months.
What is aXichem AB Class A’s market cap?
aXichem AB Class A’s market cap is €7.80M.
When is aXichem AB Class A’s upcoming earnings report date?
aXichem AB Class A’s upcoming earnings report date is Aug 27, 2026 which is in 78 days.
How were aXichem AB Class A’s earnings last quarter?
aXichem AB Class A released its earnings results on May 21, 2026. The company reported -€0.012 earnings per share for the quarter, the consensus estimate of -€0.012 by €0.
Is aXichem AB Class A overvalued?
According to Wall Street analysts aXichem AB Class A’s price is currently Overvalued.
Does aXichem AB Class A pay dividends?
aXichem AB Class A does not currently pay dividends.
What is aXichem AB Class A’s EPS estimate?
aXichem AB Class A’s EPS estimate is -0.01.
How many shares outstanding does aXichem AB Class A have?
aXichem AB Class A has 67,729,120 shares outstanding.
What happened to aXichem AB Class A’s price movement after its last earnings report?
aXichem AB Class A reported an EPS of -€0.012 in its last earnings report, expectations of -€0.012. Following the earnings report the stock price went up 4.301%.
Which hedge fund is a major shareholder of aXichem AB Class A?
Currently, no hedge funds are holding shares in DE:A6X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
aXichem AB Class A
aXichem AB is a biotechnology firm, established in 2007 and headquartered in Malmö, Sweden, that specializes in creating natural analogue compounds. The company offers aXivite, a capsaicin analogue solution designed for various dietary health applications. Another key product, aXiphen-bio, functions as a biological repellent, providing antifouling protection for marine vessels and installations, and managing pests in agriculture, forestry, and for safeguarding cable infrastructure both within buildings and underground. Additionally, aXiphen-feed is developed to boost the health of poultry, including chickens and hens, as well as swine, such as pigs and piglets.
Technical Analysis
Nexam Chemical Holding AB
―
―
Svenska Aerogel Holding AB
―
OrganoClick AB
―
XP Chemistries AB
―